EligibleTrials

The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting · NCT05626348 · Interventional (participants receive a specific treatment) · Lead sponsor: Qilu Hospital of Shandong University

View the official record on ClinicalTrials.gov →
Rheumatoid arthritis

Interventions studied

Adalimumab InjectionHydroxychloroquineIguratimodLeflunomideMethotrexate

What this trial is about

This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.

Who can take part

Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.